Drugs / Dopaminergic progenitor cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06687837 | Apr 2025 → Dec 2027 expected | Parkinson disease | Jeffrey S. Schweitzer, MD, PhD | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dopaminergic progenitor cells | “Dopaminergic progenitor cells derived from autologous induced pluripotent stem cells will be injected into the brain in two cohorts of Parkinson's patients, one receiving low...” NCT06687837 ↗ |
| Modality | Cell therapy | “autologous midbrain dopaminergic progenitor cell (mDAP) transplantation” NCT06687837 ↗ |
| Route | Other | “will be injected into the brain” NCT06687837 ↗ |